Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IFEM trial of pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in women with advanced NSCLC and high PD-L1
2026-525387-18-00Phase 3Authorised
- Sponsor
- German Cancer Research Center
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by German Cancer Research Center. Primary endpoint: Progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2026-525387-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525387-18-00.